<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970787</url>
  </required_header>
  <id_info>
    <org_study_id>B-250</org_study_id>
    <nct_id>NCT01970787</nct_id>
  </id_info>
  <brief_title>A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System</brief_title>
  <acronym>AIN</acronym>
  <official_title>A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Single-center prospective pilot trial involving up to 22 subjects. This study will
      assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) to the anal
      canal using the FDA cleared HALO Ablation System to eradicate anal HSIL lesions in
      HIV-negative subjects with intra-anal intraepithelial neoplasia (AIN). The study intervention
      will demonstrate that a reasonable proportion of subjects will be histologically cleared of
      their anal HSIL within the ETZ in a tolerable and relatively safe manner
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL)</measure>
    <time_frame>12 months</time_frame>
    <description>Participants with histologic clearance of anal HSIL within the ETZ (eligible treatment zone) at 12 months from first RFA treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Ease of Technique</measure>
    <time_frame>12 months</time_frame>
    <description>Technical feasibility of applying RFA to the anal canal. Physician's assessment of ablation as optimal (complete ablation) versus sub-optimal (incomplete ablation)in the affected area in the anal canal.
Data not collected and could not be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>Subject tolerability of the RFA procedure as measured by severity. Mild: Awareness of signs and symptoms, but easily tolerated; are of a minor irritant type; causing no loss of time from normal activities; symptoms would not require medication or a medical intervention; asymptomatic lab findings; marginal clinical relevance; signs and symptoms are transient.
Moderate: Discomfort severe enough to cause interference with usual activities; minimal intervention.
Severe: Incapacitating with inability to do work or usual activities; signs and symptoms may be of systemic nature or require medical evaluation or treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Any related adverse event occuring in patients enrolled in this study. Event type and relationship to the device or procedure will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of HSIL to Cancer</measure>
    <time_frame>12 months</time_frame>
    <description>Histologic progression of HSIL to cancer as measured in biopsies read at the central pathology lab. Data not collected and could not be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency Ablation (RFA) using the HALO Ablation System</intervention_name>
    <arm_group_label>RFA</arm_group_label>
    <other_name>Barrx Ablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  HRA 2 to 12 weeks prior to the 0 month RFA visit yielding one or more flat,
             non-condylomatous biopsy-proven HSILs that are

               1. Located entirely within in the eligible treatment zone

               2. Contiguous with the squamocolumnar junction Eligible treatment zone (ETZ) is
                  defined as

               1. 3 cm above the dentate line to the anocutaneous line

               2. Half of the anorectal circumference (meaning no more than two contiguous
                  quadrants)

          -  If female of child-bearing age, negative pregnancy test within 8 weeks of the 0 month
             RFA visit and declared intent to remain on birth control throughout the trial, or,
             declaration of infertility defined as subject report of status as post-menopausal or
             surgically sterile (status post hysterectomy or tubal ligation).

          -  HIV negative, ELISA/Western blot test obtained within 12 weeks of the 0 month RFA
             visit

        Exclusion Criteria:

          1. Any biopsy-proven HSIL entirely outside of the ETZ

          2. Any biopsy-proven HSIL partially within the ETZ (for example, an HSIL lesion with
             extension to the perianal skin)

          3. Any condylomas in the eligible treatment zone &gt; 1/2 cm diameter

             â€¢ Note: Condylomas in the eligible treatment zone &lt; 1/2 cm in diameter must be excised
             or cauterized (not treated topically or with IRC) before or during Visit 1 (0 month
             RFA visit)

          4. Any anal or rectal pathology requiring treatment including ulcer, fistula, fissure,
             stenosis or proctitis

          5. History of or present anal or rectal cancer

          6. History of pelvic radiation therapy

          7. History of HPV vaccination or plans to initiate HPV vaccination during the trial

          8. History of ablation or resection therapy within the ETZ other than cauterization or
             excision of condyloma(s)

          9. History of topical therapy (Imiquimod, 5-FU) within 6 months prior to the 0 month RFA
             visit within the ETZ

         10. Hemorrhoids &gt; grade II

         11. Fecal incontinence (that the investigator feels may impair healing)

         12. Concurrent disease requiring systemic immunosuppression therapy

         13. Concurrent malignancy requiring systemic therapy

         14. Life expectancy &lt; 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laser Surgery Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <results_first_submitted>April 26, 2016</results_first_submitted>
  <results_first_submitted_qc>June 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2016</results_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RFA Treatment</title>
          <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV-negative subjects with AIN containing HSIL located within half of the anorectal circumference, which is defined as no more than two contiguous quadrants and in the study referred to as the eligible treatment zone (ETZ).</population>
      <group_list>
        <group group_id="B1">
          <title>RFA Treatment</title>
          <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="32" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL)</title>
        <description>Participants with histologic clearance of anal HSIL within the ETZ (eligible treatment zone) at 12 months from first RFA treatment</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RFA Treatment</title>
            <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL)</title>
          <description>Participants with histologic clearance of anal HSIL within the ETZ (eligible treatment zone) at 12 months from first RFA treatment</description>
          <units>participants w histological clearance</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility and Ease of Technique</title>
        <description>Technical feasibility of applying RFA to the anal canal. Physician's assessment of ablation as optimal (complete ablation) versus sub-optimal (incomplete ablation)in the affected area in the anal canal.
Data not collected and could not be analyzed</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RFA Treatment</title>
            <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility and Ease of Technique</title>
          <description>Technical feasibility of applying RFA to the anal canal. Physician's assessment of ablation as optimal (complete ablation) versus sub-optimal (incomplete ablation)in the affected area in the anal canal.
Data not collected and could not be analyzed</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability</title>
        <description>Subject tolerability of the RFA procedure as measured by severity. Mild: Awareness of signs and symptoms, but easily tolerated; are of a minor irritant type; causing no loss of time from normal activities; symptoms would not require medication or a medical intervention; asymptomatic lab findings; marginal clinical relevance; signs and symptoms are transient.
Moderate: Discomfort severe enough to cause interference with usual activities; minimal intervention.
Severe: Incapacitating with inability to do work or usual activities; signs and symptoms may be of systemic nature or require medical evaluation or treatment.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RFA Treatment</title>
            <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <description>Subject tolerability of the RFA procedure as measured by severity. Mild: Awareness of signs and symptoms, but easily tolerated; are of a minor irritant type; causing no loss of time from normal activities; symptoms would not require medication or a medical intervention; asymptomatic lab findings; marginal clinical relevance; signs and symptoms are transient.
Moderate: Discomfort severe enough to cause interference with usual activities; minimal intervention.
Severe: Incapacitating with inability to do work or usual activities; signs and symptoms may be of systemic nature or require medical evaluation or treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>bleeding associated with bowel movements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anal bleeding without a bowel movement, mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anal bleeding without a bowel movement, moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe bleeding associated with a bowel movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Any related adverse event occuring in patients enrolled in this study. Event type and relationship to the device or procedure will be measured.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RFA Treatment</title>
            <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Any related adverse event occuring in patients enrolled in this study. Event type and relationship to the device or procedure will be measured.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression of HSIL to Cancer</title>
        <description>Histologic progression of HSIL to cancer as measured in biopsies read at the central pathology lab. Data not collected and could not be analyzed.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RFA Treatment</title>
            <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>Progression of HSIL to Cancer</title>
          <description>Histologic progression of HSIL to cancer as measured in biopsies read at the central pathology lab. Data not collected and could not be analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RFA Treatment</title>
          <description>Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
Radiofrequency Ablation (RFA) using the HALO Ablation System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anal pocket with purulent discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen E Goldstone</name_or_title>
      <organization>Laser Surgery Care</organization>
      <phone>212-242-6500</phone>
      <email>segmd@prodigy.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

